Q/C Technologies Insider Trades
NASDAQ: QCLSHealth CareBiotechnology: In Vitro & In Vivo Diagnostic SubstancesUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
Last 12 months
- Purchases
- 1 · $5.52K
- Sales
- 0 · $0
- Shares bought / sold
- 1.75K / 0
- Net activity
- Net buying $5,522
Q/C Technologies insider activity
Over the last 12 months, Q/C Technologies insiders reported 8 transactions on SEC Form 4: 1 open-market purchase and 0 sales. Insiders bought $5,522 and sold $0 worth of stock, for net insider buying of $5,522. The most recent filing shows PharmaCyte Biotech, Inc. (10% Owner) reporting a transaction in 4,982,272 shares on Nov 18, 2026.
Insider sales are common for compensation, tax and diversification reasons, while open-market purchases are rarer; tracking both helps put QCLS's ownership changes in context.
Summary generated from market data by MetaCap's automated system. Methodology
QCLS insider transactions
| Date | Insider | Type | Shares | Value | Filing |
|---|---|---|---|---|---|
| Nov 18, 2026 | PharmaCyte Biotech, Inc.10% Owner | Option exercise | 4,982,272 | — | Form 4 |
| Oct 1, 2026 | Silverman JoshuaExecutive Chairman | Award | 77,390 | — | Form 4 |
| Jul 10, 2026 | Silverman JoshuaExecutive Chairman | Award | 16,620 | — | Form 4 |
| Apr 13, 2026 | Silverman JoshuaExecutive Chairman | Award | 162,162 | — | Form 4 |
| Apr 13, 2026 | Silverman JoshuaExecutive Chairman | Award | 16,806 | — | Form 4 |
| Mar 30, 2026 | Voss Chelsea SierraDirector | Buy | 1,753 | $5.52K | Form 4 |
| Jan 16, 2026 | Voss Chelsea SierraDirector | Award | 25,000 | — | Form 4 |
| Jan 16, 2026 | Voss Chelsea SierraDirector | Award | 212,500 | — | Form 4 |
| Nov 14, 2025 | RAUCH GARY MVice President of Finance | Award | 11,420 | — | Form 4 |
| Nov 14, 2025 | Silverman JoshuaExecutive Chairman | Award | 91,356 | — | Form 4 |
| Nov 14, 2025 | Bernstein BruceDirector | Award | 25,000 | — | Form 4 |
| Nov 14, 2025 | Friscia StephenDirector | Award | 22,839 | — | Form 4 |
| Nov 14, 2025 | Glass MitchellDirector, Chief Medical Off. | Award | 11,420 | — | Form 4 |
| Nov 14, 2025 | White Billy JoeDirector | Award | 22,839 | — | Form 4 |
| Oct 3, 2025 | White Billy JoeDirector | Award | 2,161 | — | Form 4 |
| Oct 3, 2025 | Glass MitchellDirector, Chief Medical Off. | Award | 1,080 | — | Form 4 |
| Oct 3, 2025 | RAUCH GARY MVice President of Finance | Award | 1,080 | — | Form 4 |
| Oct 3, 2025 | Friscia StephenDirector | Award | 2,161 | — | Form 4 |
| Oct 3, 2025 | Silverman JoshuaExecutive Chairman | Award | 8,644 | — | Form 4 |
| Aug 24, 2023 | Rivard PaulChief Legal Officer | Buy | 150,000 | $166.50K | Form 4 |
| Aug 17, 2023 | Rivard PaulChief Legal Officer | Buy | 25,000 | $28.08K | Form 4 |
| Dec 8, 2022 | Rivard PaulEVP of Operations, GC | Buy | 10,000 | $15.30K | Form 4 |
| Nov 26, 2021 | Silverman JoshuaDirector | Buy | 5,000 | $37.77K | Form 4 |
| Nov 24, 2021 | Silverman JoshuaDirector | Buy | 3,266 | $23.17K | Form 4 |
| Nov 24, 2021 | Silverman JoshuaDirector | Buy | 6,734 | $42.42K | Form 4 |
| Nov 23, 2021 | Rivard PaulEVP of Operations, GC | Buy | 15,000 | $90.45K | Form 4 |
Transaction codes follow SEC Form 4: P = open-market purchase, S = open-market sale, A = grant or award, M = option exercise, F = shares withheld for taxes. About Form 4